Luke Evnin Sells 62,970 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Posted by Joseph Casey on May 20th, 2026

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) Director Luke Evnin sold 62,970 shares of Werewolf Therapeutics stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $0.45, for a total value of $28,336.50. Following the completion of the transaction, the director owned 1,041,342 shares of the company’s stock, valued at approximately $468,603.90. This trade represents a 5.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

On Wednesday, May 20th, Luke Evnin sold 85,895 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.43, for a total value of $36,934.85.
On Monday, May 18th, Luke Evnin sold 22,184 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.50, for a total value of $11,092.00.
On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total value of $43,446.40.
On Monday, May 11th, Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total value of $22,745.16.
On Friday, May 8th, Luke Evnin sold 305,741 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.70, for a total value of $214,018.70.
On Thursday, May 7th, Luke Evnin sold 79,086 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $49,824.18.
On Wednesday, May 6th, Luke Evnin sold 14,635 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.66, for a total value of $9,659.10.
On Tuesday, May 5th, Luke Evnin sold 6,860 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.69, for a total value of $4,733.40.
On Monday, May 4th, Luke Evnin sold 47,963 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.72, for a total value of $34,533.36.
On Friday, May 1st, Luke Evnin sold 58,394 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.73, for a total value of $42,627.62.

Werewolf Therapeutics Stock Performance

Werewolf Therapeutics stock traded up $0.01 during midday trading on Wednesday, hitting $0.44. 1,033,082 shares of the company’s stock were exchanged, compared to its average volume of 460,756. Werewolf Therapeutics, Inc. has a 52-week low of $0.40 and a 52-week high of $2.38. The stock has a 50-day moving average price of $0.80 and a two-hundred day moving average price of $0.79. The company has a market cap of $21.29 million, a P/E ratio of -0.35 and a beta of 0.41.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.04. As a group, sell-side analysts expect that Werewolf Therapeutics, Inc. will post -1.29 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on HOWL shares. Wall Street Zen lowered Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Werewolf Therapeutics presently has an average rating of “Hold” and a consensus target price of $3.75.

View Our Latest Research Report on HOWL

Institutional Investors Weigh In On Werewolf Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of HOWL. Bank of America Corp DE raised its position in Werewolf Therapeutics by 1.2% during the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after purchasing an additional 25,882 shares during the last quarter. Vanguard Group Inc. raised its position in Werewolf Therapeutics by 8.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after purchasing an additional 109,796 shares during the last quarter. Renaissance Technologies LLC raised its position in Werewolf Therapeutics by 48.6% during the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock valued at $429,000 after purchasing an additional 221,766 shares during the last quarter. Jane Street Group LLC bought a new position in Werewolf Therapeutics during the 2nd quarter valued at approximately $409,000. Finally, Citadel Advisors LLC bought a new position in Werewolf Therapeutics during the 3rd quarter valued at approximately $304,000. Institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

(Get Free Report)

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.